Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque Psoriasis

被引：0
|
作者：
Blauvelt, Andrew [1 ]
Green, Lawrence J. [2 ]
Lebwohl, Mark G. [3 ]
Yamauchi, Paul S. [4 ]
Lin, Tina [5 ]
Martin, Gina [6 ]
Pillai, Radhakrishnan [6 ]
机构：
[1] Oregon Med Res Ctr, Portland, OR 97223 USA
[2] George Washington Univ, Sch Med, Dept Dermatol, Washington, DC USA
[3] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[4] Clin Sci Inst, Santa Monica, CA USA
[5] Ortho Dermatol, Bridgewater, NJ USA
[6] Bausch Hlth Amer Inc, Petaluma, CA USA
来源：
JOURNAL OF DRUGS IN DERMATOLOGY | 2019年 / 18卷 / 03期
关键词：
PHYSICIAN GLOBAL ASSESSMENT; BODY-SURFACE AREA; APREMILAST; SAFETY;
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：297 / 299
页数：3
相关论文
共 50 条
  • [41] Treatment of moderate to severe acne with once-daily tazarotene 0.045% lotion in males: Pooled analysis of two phase 3 studies
    Weiss, Jonathan S.
    Bhatia, Neal
    Gold, Linda Stein
    Martin, Gina
    Pillai, Radhakrishnan
    Guenin, Eric
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB144 - AB144
  • [42] Impact of body mass index (BMI) on the efficacy and safety of halobetasol propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion in patients with plaque psoriasis
    Lebwohl, Mark G.
    Del Rosso, James Q.
    Alonso-Llamazares, Javier
    Lattouf, Mark
    Jacobson, Abby
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB130 - AB130
  • [43] Real-world treatment outcomes with halobetasol propionate 0.01%/ tazarotene 0.045% lotion in patients with mild-to-moderate plaque psoriasis: A Canadian multicenter retrospective chart review
    Vender, Ronald
    Turchin, Irina
    Lansang, Perla
    Prajapati, Vimal H.
    Legault, Mark
    Barakat, Maxime
    Yeung, Jensen
    JAAD INTERNATIONAL, 2022, 8 : 60 - 63
  • [44] Safety and Efficacy of Halobetasol Propionate Lotion 0.01% in the Treatment of Moderate to Severe Plaque Psoriasis: A Pooled Analysis of 2 Phase 3 Studies
    Sugarman, Jeffrey L.
    Weiss, Jonathan S.
    Tanghetti, Emil A.
    Soung, Jennifer
    Yamauchi, Paul S.
    Lin, Tina
    Harris, Susan
    Martin, Gina
    Pillai, Radhakrishnan
    CUTIS, 2019, 103 (02): : 111 - +
  • [45] Fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion for the treatment of plaque psoriasis in patients with 3-5% body surface area (BSA) and poor quality of life (QoL)
    Gold, Linda Stein
    Lain, Edward
    Bagel, Jerry
    Jacobson, Abby
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB156 - AB156
  • [46] Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Impact of Gender and Race on Efficacy and Safety
    Lain, Edward
    Day, Doris
    Harper, Julie
    Guenin, Eric
    JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (11) : 1128 - 1138
  • [47] Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris in a preadolescent population
    Eichenfield, Lawrence F.
    Sugarman, Jeffrey L.
    Guenin, Eric
    Harris, Susan
    Bhatt, Varsha
    PEDIATRIC DERMATOLOGY, 2019, 36 (02) : 193 - 199
  • [48] Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in an Asian Population
    Han, George
    Armstrong, April W.
    Desai, Seemal R.
    Guenin, Eric
    JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (09) : 910 - 916
  • [49] Novel Tretinoin 0.05% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in a Hispanic Population
    Cook-Bolden, Fran E.
    Weinkle, Susan H.
    Guenin, Eric
    Bhatt, Varsha
    JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (01) : 32 - 38
  • [50] Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD
    Buhl, Roland
    Banerji, Donald
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2012, 7 : 729 - 741
12345